Laurent Cany

2.9k total citations
38 papers, 1.2k citations indexed

About

Laurent Cany is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Laurent Cany has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 6 papers in Physiology. Recurrent topics in Laurent Cany's work include Colorectal Cancer Treatments and Studies (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers) and Cancer Treatment and Pharmacology (6 papers). Laurent Cany is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (6 papers) and Cancer Treatment and Pharmacology (6 papers). Laurent Cany collaborates with scholars based in France, Belgium and United States. Laurent Cany's co-authors include Pierre Soubeyran, Alain Ravaud, J. Ceccaldi, Jean‐Frédéric Blanc, Jérôme Dauba, Nadine Houédé, C. Blanc-Bisson, Marianne Fonck, M. Rainfray and Carine Bellera and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Laurent Cany

36 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laurent Cany France	15	709	350	336	332	144	38	1.2k
Lucia Fratino Italy	16	673 0.9×	421 1.2×	366 1.1×	278 0.8×	76 0.5×	75	1.4k
Véronique Girre France	13	556 0.8×	445 1.3×	291 0.9×	260 0.8×	60 0.4×	21	1.1k
Nicolò Matteo Luca Battisti United Kingdom	21	922 1.3×	359 1.0×	398 1.2×	219 0.7×	130 0.9×	81	1.6k
Antonella Venturino Italy	14	533 0.8×	249 0.7×	279 0.8×	139 0.4×	67 0.5×	57	953
Jean-Pierre Droz France	12	795 1.1×	520 1.5×	575 1.7×	340 1.0×	106 0.7×	12	2.0k
S. Klapper United States	5	561 0.8×	708 2.0×	327 1.0×	387 1.2×	67 0.5×	7	1.3k
Jérôme Dauba France	14	738 1.0×	363 1.0×	497 1.5×	355 1.1×	40 0.3×	54	1.3k
N. Maisey United Kingdom	15	671 0.9×	191 0.5×	326 1.0×	110 0.3×	130 0.9×	30	1.1k
Richard M. Levine United States	13	578 0.8×	435 1.2×	329 1.0×	244 0.7×	52 0.4×	34	1.2k
E. Maartense Netherlands	17	1.3k 1.8×	244 0.7×	427 1.3×	187 0.6×	331 2.3×	49	2.0k

Countries citing papers authored by Laurent Cany

Since Specialization

Citations

This map shows the geographic impact of Laurent Cany's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurent Cany with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurent Cany more than expected).

Fields of papers citing papers by Laurent Cany

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurent Cany. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurent Cany. The network helps show where Laurent Cany may publish in the future.

Co-authorship network of co-authors of Laurent Cany

This figure shows the co-authorship network connecting the top 25 collaborators of Laurent Cany. A scholar is included among the top collaborators of Laurent Cany based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurent Cany. Laurent Cany is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lepage, Côme, Jean–Marc Phelip, Laurent Cany, et al.. (2020). 398O Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial. Annals of Oncology. 31. S410–S410. 5 indexed citations

Évrard, Serge, G. Désolneux, Carine Bellera, et al.. (2019). Systemic chemotherapy plus cetuximab after complete surgery in the treatment of isolated colorectal peritoneal carcinoma: COCHISE phase II clinical trial. BMC Research Notes. 12(1). 450–450. 2 indexed citations

Lepage, Côme, Laurent Cany, E. Maillard, et al.. (2016). Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics. Annals of Oncology. 27. vi159–vi159. 3 indexed citations

Cany, Laurent, et al.. (2015). Enzalutamide and sleep apnea: an emerging central nervous system side-effect?. Annals of Oncology. 27(1). 206–206. 4 indexed citations

Bourdel‐Marchasson, Isabelle, C. Blanc-Bisson, A. Doussau, et al.. (2014). Nutritional Advice in Older Patients at Risk of Malnutrition during Treatment for Chemotherapy: A Two-Year Randomized Controlled Trial. PLoS ONE. 9(9). e108687–e108687. 98 indexed citations

Bécouarn, Y., Laurent Cany, Marina Pulido, et al.. (2014). FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Research Notes. 7(1). 260–260. 17 indexed citations

Hoppe, Stéphanie, M. Rainfray, Marianne Fonck, et al.. (2013). Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy. Journal of Clinical Oncology. 31(31). 3877–3882. 174 indexed citations

Pivot, X., Gilles Romieu, Marc Debled, et al.. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. The Lancet Oncology. 14(8). 741–748. 211 indexed citations

Roca, Lise, Véronique Dièras, Henri Roché, et al.. (2013). Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial. Breast Cancer Research and Treatment. 139(3). 789–800. 48 indexed citations

10.

Floquet, Anne, et al.. (2013). Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study. Cancer Chemotherapy and Pharmacology. 73(1). 61–68. 3 indexed citations

11.

Soubeyran, Pierre, Marianne Fonck, C. Blanc-Bisson, et al.. (2012). Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer. Journal of Clinical Oncology. 30(15). 1829–1834. 305 indexed citations

12.

Fonck, Marianne, René Brunet, Y. Bécouarn, et al.. (2011). Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: A first-line phase II study. Clinics and Research in Hepatology and Gastroenterology. 35(12). 823–830. 12 indexed citations

13.

Bécouarn, Y., Pierre Sénesse, Simon Thézenas, et al.. (2007). A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5–FU2 + irinotecan or LV5–FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. Annals of Oncology. 18(12). 2000–2005. 11 indexed citations

14.

Soubeyran, Pierre, Alain Monnereau, Houchingue Eghbali, et al.. (2005). Fludarabine phosphate–CVP in patients over 60 years of age with advanced, low-grade and follicular lymphoma: A dose-finding study. European Journal of Cancer. 41(17). 2630–2636.

15.

Tchen, Nadine, Pierre Soubeyran, Houchingue Eghbali, et al.. (2002). Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients. Critical Reviews in Oncology/Hematology. 43(3). 219–226. 7 indexed citations

16.

Cany, Laurent, et al.. (1999). Prognostic factors in superficial adult soft tissue sarcomas: Analysis of a series of 105 patients. Journal of Surgical Oncology. 71(1). 4–9. 21 indexed citations

17.

Ravaud, Alain, Christine Chevreau, Laurent Cany, et al.. (1998). Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.. Journal of Clinical Oncology. 16(9). 2930–2936. 31 indexed citations

18.

Ravaud, Alain, E. Legrand, M. Delaunay, et al.. (1995). A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma. British Journal of Cancer. 71(2). 331–336. 19 indexed citations

19.

Ravaud, Alain, Sylvie Négrier, Laurent Cany, et al.. (1994). Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. British Journal of Cancer. 69(6). 1111–1114. 31 indexed citations

20.

Vergier, B., et al.. (1993). Expression of MDR1/P glycoprotein in human sarcomas. British Journal of Cancer. 68(6). 1221–1226. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact